Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib

Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib

Recent efforts to personalize treatment with platinum-based chemotherapy and PARP inhibitors have produced promising results in homologous recombinant deficient (HRD) metastatic pancreatic cancer (MPC). However, new strategies are necessary to overcome resistance. The below case series documents pat...

Full description

Bibliographic Details
Main Authors: Gehan Botrus, Denise Roe, Gayle S. Jameson, Pedro Luiz Serrano Uson Junior, Ronald Lee Korn, Lana Caldwell, Taylor Bargenquast, Max Miller, Erkut Hasan Borazanci
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Biomedicines
Subjects:
pancreatic cancer
BRCA
Olaparib
homologous recombination deficient
mitomycin
Online Access:https://www.mdpi.com/2227-9059/10/11/2705

Internet

https://www.mdpi.com/2227-9059/10/11/2705

Similar Items